NCT05934292View on ClinicalTrials.gov

Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Renal Impairment Study (MK-0616-020)

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

July 20, 2023

Primary Completion Date

January 19, 2024

Study Completion Date

January 19, 2024

Conditions
Hypercholesterolaemia
Interventions
DRUG

Enlicitide Decanoate

Oral dose

Trial Locations (5)

32809

Orlando Clinical Research Center ( Site 0004), Orlando

33009

Velocity Clinical Research, Hallandale Beach ( Site 0003), Hallandale

33147

Advanced Pharma CR, LLC ( Site 0001), Miami

33603

Genesis Clinical Research, LLC ( Site 0002), Tampa

33014-3616

Clinical Pharmacology of Miami ( Site 0005), Miami

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY